Search clinical trials for: Long-term Extension

Total 3349 results

Ultragenyx Pharmaceutical Inc

Not yet recruiting

Long-term Extension of GTX-102 in Angelman Syndrome

Angelman Syndrome

United States, Australia, Canada, Germany, United Kingdom, Israel, France, Spain
Novartis Pharmaceuticals

Recruiting

Long-term Extension Study of Ligelizumab in Food Allergy

Food Allergy

Spain, France, Germany, Italy, United States, Netherlands, Canada, Japan, Australia
GlaxoSmithKline
Iqvia Pty Ltd

Recruiting

An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) (AGILE)

Asthma

United States, Australia, Canada, France, Germany, Italy, Japan, Poland, Spain, China, Czechia, Hungary, Taiwan, United Kingdom
BeiGene

Recruiting

Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies

B-cell Malignancies

China, Italy, United States, Spain, United Kingdom, Poland, Czechia, Netherlands, Greece, France, Sweden, Korea, Republic of, Turkey
Merck Sharp & Dohme LLC

Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Solid Tumors | Hematologic Malignancies

United States, Poland, Brazil, Ukraine, Argentina, Australia, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic... and more
Alzheon Inc.

Enrolling by invitation

Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects (APOLLOE4-LTE)

Early Alzheimer's Disease

United States, Spain, Canada, Netherlands, Czechia, United Kingdom, France, Germany, Iceland
Organon and Co
Meiji Seika Pharma Co., Ltd.

Completed

Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)

Schizophrenia
Alkermes, Inc.

Enrolling by invitation

Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects

Schizophrenia | Bipolar I Disorder

United States, Argentina, Brazil, Colombia, Mexico
Diurnal Limited

Enrolling by invitation

Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia

Congenital Adrenal Hyperplasia

United States, France, Japan
LEO Pharma

Active, not recruiting

Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND

Atopic Dermatitis

United States, Belgium, Canada, Czechia, France, Germany, Italy, Japan, Poland, Spain, United Kingdom
AbbVie

Enrolling by invitation

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR (Maia)

Ocular Hypertension | Open-Angle Glaucoma

United States, Argentina, Belgium, Brazil, Canada, Colombia, Czechia, Denmark, Egypt, France, Germany, Hong Kong, Italy, Korea, Republic of, New Zealand, Peru, Philippines, Poland, Russian Federation, Singapore, South Africa, Spain, Thailan... and more
AbbVie

Enrolling by invitation

Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine

Episodic Migraine

United States, Canada, Denmark, Hungary, Italy, Poland, Puerto Rico, Spain, United Kingdom, Israel, Japan, Sweden
Actelion

Completed

Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis (OPTIMUM-LT)

Multiple Sclerosis

United States, Spain, Hungary, Israel, Portugal, Germany, Russian Federation, Belarus, Poland, Serbia, Latvia, Turkey, Croatia, Canada, Czechia, Bulgaria, Bosnia and Herzegovina, Finland, France, Georgia, Greece, Italy, Lithuania, Mexico and more
Medytox Korea

Completed

Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines

Glabellar Frown Lines

Korea, Republic of
Daiichi Sankyo Co., Ltd.

Active, not recruiting

Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Japan
Ultragenyx Pharmaceutical Inc
Mereo BioPharma

Terminated

Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta

Osteogenesis Imperfecta

United States
Adverum Biotechnologies, Inc.

Active, not recruiting

Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

Neovascular Age-related Macular Degeneration | Wet Age-related Macular Degeneration

United States
AbbVie

Enrolling by invitation

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

Migraine

United States, Puerto Rico
GlaxoSmithKline

Completed

Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529

Hypertension, Pulmonary

France, United States, Germany, Spain, Italy, Japan, Hungary, Russian Federation, Argentina
H. Lundbeck A/S

Terminated

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

Depressive Disorder, Major

United States, Korea, Republic of, Hungary, Poland, Spain, Serbia, Estonia, Bulgaria, Latvia, Russian Federation, Ukraine, Canada, Colombia, France, Germany, Israel, Italy, Mexico, South Africa, United Kingdom
Adverum Biotechnologies, Inc.

Enrolling by invitation

Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)

Diabetic Retinopathy | Diabetic Macular Edema

United States, Puerto Rico
Alexion Pharmaceuticals

Completed

An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients

Neuromyelitis Optica | Neuromyelitis Optica Spectrum Disorder

Hong Kong, Korea, Republic of, United States, Croatia, Australia, Canada, Malaysia, Japan, Italy, Turkey, Spain, Taiwan, Argentina, Colombia, Czechia, Denmark, Germany, Russian Federation, Thailand, United Kingdom
Durect
Hospira, now a wholly owned subsidiary of Pfizer; Nycomed

Completed

An Extension Trial to Evaluate Long-term Safety of SABER™-Bupivacaine for Pain Following Shoulder Surgery

Pain

New Zealand, Australia
Sumitomo Pharma Co., Ltd.

Completed

Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

Schizophrenia

Japan, Korea, Republic of, Malaysia, Taiwan
Tricida, Inc.

Completed

Long-term Safety Extension to Study TRCA-301

Metabolic Acidosis

United States, Bulgaria, Georgia, Hungary, Serbia, Slovenia, Ukraine
AbbVie

Terminated

A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib

Rheumatoid Arthritis (RA)

Belgium, Canada, Czechia, Hungary, Poland, Spain, United Kingdom
ReveraGen BioPharma, Inc.
University of Pittsburgh; Cooperative International Neuromuscular Research...

Completed

Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States, Canada, United Kingdom, Sweden, Australia, Israel
Boston Scientific Corporation

Completed

AIR Extension Study - Long-Term Safety of Alair Treated Subjects (AIRx)

Asthma

Canada, Brazil, United Kingdom
Novartis Pharmaceuticals

Terminated

Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients

Pulmonary Arterial Hypertension

Germany, United Kingdom, United States
GlaxoSmithKline
Bausch Health Americas, Inc.

Terminated

Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS

Epilepsy

United States
GlaxoSmithKline

Completed

A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622

Hypereosinophilic Syndrome

United States, Poland, Spain, France, Belgium, Germany, Argentina, Russian Federation, Mexico, Italy, Brazil, United Kingdom, Romania
Purdue Pharma LP

Completed

Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.

Chronic Nonmalignant and Nonneuropathic Pain

United States
Santen Inc.

Completed

A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program (SPRING)

Non-Infectious Uveitis of the Posterior Segment of the Eye

United States, France, Turkey, Italy, Austria, India
BioDelivery Sciences International

Completed

Long-term Extension Study of BEMA™ Fentanyl

Respiratory Depression
GlaxoSmithKline

Terminated

Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects

Diabetes Mellitus, Type 2

United States
AstraZeneca

Completed

Long-term Follow-up of antithrombotIc Management Patterns in Acute Coronary Syndrome Patients in Asia-China Extension (EPICOR)

Acute Coronary Syndromes

China
H. Lundbeck A/S

Completed

Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease (STAR Extension)

Alzheimer's Disease

Germany, United States, Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Estonia, Finland, France, Hungary, Israel, Italy, Korea, Republic of, Lithuania, Poland, Portugal, Romania, South Africa, Spain, Taiwan and more
AbbVie

Terminated

Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)

Schizophrenia

United States, Russian Federation, United Kingdom
Bayer

Completed

Long-term Pre-dialysis Extension in Europe and Asia Pacific (DIALOGUE 3)

Renal Insufficiency, Chronic | Anemia

United Kingdom, France, Spain, Japan, Hungary, Korea, Republic of, Israel, Italy, Bulgaria, Australia, Germany, Poland, Romania, Turkey
AstraZeneca

Completed

Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)

Chronic Obstructive Pulmonary Disease

United States, Canada
AbbVie (prior sponsor, Abbott)

Completed

Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact (DAPHNE)

Advanced Idiopathic Parkinson's Disease
Novartis Pharmaceuticals

Completed

Ext. Long-term Safety Study in CF Patients: Single Arm TIP

Long-term Safety of TIP

Italy, Spain, Germany, United States, Australia, Canada, Hungary, Mexico, Argentina
Mitsubishi Tanabe Pharma Corporation

Terminated

Long-term Extension Study of MCI-196

Chronic Kidney Disease | Hyperphosphatemia | Dialysis | Paediatric

United Kingdom
Bayer
Shire

Completed

Long-term Study in Chronic Kidney Disease (Extension From Study 14817)

Hyperphosphatemia

Japan
UCB Pharma

Terminated

Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease

Parkinson's Disease

Spain, South Africa, New Zealand, Hungary, United States, Germany, Italy, Australia, Finland, United Kingdom, Poland
Takeda

Completed

Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)

Gastric Ulcers | Duodenal Ulcers

Japan
Takeda

Completed

Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin

Gastric Ulcers | Duodenal Ulcers

Japan
H. Lundbeck A/S

Completed

Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

Major Depressive Disorder
H. Lundbeck A/S

Completed

Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

Major Depressive Disorder
Bayer

Completed

Long-term Extension From RCC Phase II (11515)

Carcinoma, Renal Cell

Japan

Search clinical trials for: Long-term Extension

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations